Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
MY TRIALS
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Register a trial
The ANZCTR website will be unavailable from 1pm until 3pm (AEDT) on Wednesday the 30th of October for website maintenance. Please be sure to log out of the system in order to avoid any loss of data.
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/study/NCT03023020
Registration number
NCT03023020
Ethics application status
Date submitted
29/12/2016
Date registered
18/01/2017
Titles & IDs
Public title
Management of High Bleeding Risk Patients Post Bioresorbable Polymer Coated Stent Implantation With an Abbreviated Versus Prolonged DAPT Regimen
Query!
Scientific title
Management of High Bleeding Risk Patients Post Bioresorbable Polymer Coated Stent Implantation With an Abbreviated Versus Prolonged DAPT Regimen
Query!
Secondary ID [1]
0
0
ECRI-009
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
MASTER DAPT
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
High Bleeding Risk
0
0
Query!
Coronary Artery Disease
0
0
Query!
PCI
0
0
Query!
Condition category
Condition code
Cardiovascular
0
0
0
0
Query!
Coronary heart disease
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Treatment: Drugs - Aspirin
Treatment: Drugs - P2Y12 inhibitor
Other: Abbreviated antiplatelet regimen - Dual antiplatelet therapy is discontinued immediately after randomization (i.e. 1 month post stent implantation), and a single antiplatelet agent is continued until at least 11 months post randomization (i.e. 12 months post stent implantation).
In patients on oral anticoagulants, dual antiplatelet therapy is discontinued immediately after randomization (i.e. 1 month post stent implantation), and either Aspirin or Clopidogrel is continued until 5 months post randomization (i.e. 6 months post stent implantation). Oral anticoagulation is continued until at least 11 months post randomization (i.e. 12 months post stent implantation)
Other: Prolonged antiplatelet regimen - Aspirin is continued for at least 11 months post randomization (i.e. 12 months post stent implantation), the P2Y12 inhibitor being taken at the time of randomization is continued for at least 5 months and up to 11 months post randomization (i.e. 12 months post stent implantation).
In patients on oral anticoagulants, aspirin and Clopidogrel are continued for at least 2 months post randomization (i.e. 3 months post stent implantation) and up to 11 months post randomization (i.e. 12 months after stent implantation). Either aspirin or Clopidogrel is continued up to 11 months post randomization (i.e. 12 months post stent implantation)
Treatment: Drugs: Aspirin
Dosing per current guidelines and local practice
Treatment: Drugs: P2Y12 inhibitor
Dosing per current guidelines and local practice
Query!
Intervention code [1]
0
0
Treatment: Drugs
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Net adverse clinical endpoints (NACE) defined as a composite of all-cause death, myocardial infarction, stroke and bleeding events defined as BARC 3 or 5
Query!
Assessment method [1]
0
0
Query!
Timepoint [1]
0
0
11 months
Query!
Primary outcome [2]
0
0
Major adverse cardiac and cerebral events (MACCE) defined as a composite of all-cause death, myocardial infarction and stroke
Query!
Assessment method [2]
0
0
Query!
Timepoint [2]
0
0
11 months
Query!
Primary outcome [3]
0
0
Major or clinically relevant non-major bleeding (MCB) defined as a composite of type 2, 3 and 5 BARC bleeding events
Query!
Assessment method [3]
0
0
Query!
Timepoint [3]
0
0
11 months
Query!
Secondary outcome [1]
0
0
All cause death
Query!
Assessment method [1]
0
0
Query!
Timepoint [1]
0
0
14 months
Query!
Secondary outcome [2]
0
0
Death from cardiovascular causes
Query!
Assessment method [2]
0
0
Query!
Timepoint [2]
0
0
14 months
Query!
Secondary outcome [3]
0
0
Myocardial infarction
Query!
Assessment method [3]
0
0
Query!
Timepoint [3]
0
0
14 months
Query!
Secondary outcome [4]
0
0
Stroke
Query!
Assessment method [4]
0
0
Query!
Timepoint [4]
0
0
14 months
Query!
Secondary outcome [5]
0
0
Bleeding events
Query!
Assessment method [5]
0
0
Query!
Timepoint [5]
0
0
14 months
Query!
Secondary outcome [6]
0
0
Definite or probable stent thrombosis
Query!
Assessment method [6]
0
0
Query!
Timepoint [6]
0
0
14 months
Query!
Secondary outcome [7]
0
0
Any target vessel revascularization
Query!
Assessment method [7]
0
0
Query!
Timepoint [7]
0
0
14 months
Query!
Secondary outcome [8]
0
0
Urgent target vessel revascularization
Query!
Assessment method [8]
0
0
Query!
Timepoint [8]
0
0
14 months
Query!
Secondary outcome [9]
0
0
Urgent non-target vessel revascularization
Query!
Assessment method [9]
0
0
Query!
Timepoint [9]
0
0
14 months
Query!
Secondary outcome [10]
0
0
Clinically indicated non-target vessel revascularization
Query!
Assessment method [10]
0
0
Query!
Timepoint [10]
0
0
14 months
Query!
Secondary outcome [11]
0
0
Transfusion rates both in patients with and/or without clinically detected over bleeding
Query!
Assessment method [11]
0
0
Query!
Timepoint [11]
0
0
14 months
Query!
Eligibility
Key inclusion criteria
After index PCI, patients aged 18 years or more are eligible for inclusion into the study if the following criteria are met.
1. At least one among the HBR criteria (as defined below) is met.
2. All lesions are successfully treated with Ultimaster stent in the context of routine clinical care, i.e. post-procedural angiographic diameter stenosis <20% by visual estimation
3. Free from any flow-limiting angiographic complications (i.e. significant untreated dissection or major side-branch occlusion), which require prolonged DAPT duration based on operator's opinion.
4. All stages of PCI are complete (if any) and no further PCI is planned.
At randomization visit (one month after index PCI), the following criteria must be met:
1. Fulfilment of at least one HBR criterion (as defined below), or on the basis of post-PCI actionable (i.e. requiring medical attention) non-access site related bleeding episode
2. Uneventful 30-day clinical course, i.e. free from spontaneous MI, symptomatic restenosis, stent thrombosis, stroke and any revascularization (coronary and non-coronary) requiring prolonged DAPT
3. If not on OAC,
1. Patient is on a DAPT regimen of aspirin and a P2Y12 inhibitor
2. Patient with one type of P2Y12 inhibitor for at least 7 days (i.e. no switching between oral P2Y12 inhibitors has occurred in the previous 7 days)
4. If on OAC
1. Patient is on the same type of OAC (e.g. Vitamin K antagonist or NOAC) for at least 7 days
2. Patient is on clopidogrel for at least 7 days
Definition of HBR
Post-PCI patients are at HBR if at least one of the following criteria applies:
* Clinical indication for treatment with oral anticoagulants (OAC) for at least 12 months
* Recent (<12 months) non-access site bleeding episode(s), which required medical attention (i.e. actionable bleeding).
* Previous bleeding episode(s) which required hospitalization if the underlying cause has not been definitively treated (i.e. surgical removal of the bleeding source)
* Age equal or greater than 75 years
* Systemic conditions associated with an increased bleeding risk (e.g. haematological disorders, including a history of or current thrombocytopaenia defined as a platelet count <100,000/mm3 (<100 x 109/L), or any known coagulation disorder associated with increased bleeding risk.
* Documented anaemia defined as repeated haemoglobin levels <11 g/dl or transfusion within 4 weeks before randomization.
* Need for chronic treatment with steroids or non-steroidal anti-inflammatory drugs
* Diagnosed malignancy (other than skin) considered at high bleeding risk including gastro-intestinal, genito-urethral/renal and pulmonary.
* Stroke at any time or TIA in the previous 6 months
* PRECISE DAPT score of 25 or greater
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
No limit
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
1. Treated with stents other than Ultimaster stent within 6 months prior to index procedure
2. Treated for in-stent restenosis or stent thrombosis at index PCI or within 6 months before
3. Treated with a bioresorbable scaffold at any time prior to index procedure
4. Cannot provide written informed consent
5. Under judicial protection, tutorship or curatorship
6. Unable to understand and follow study-related instructions or unable to comply with study protocol
7. Active bleeding requiring medical attention (BARC=2) on randomization visit
8. Life expectancy less than one year
9. Known hypersensitivity or allergy for aspirin, clopidogrel, ticagrelor, prasugrel, cobalt chromium or sirolimus
10. Any planned and anticipated PCI
11. Participation in another trial
12. Pregnant or breast feeding women
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Open (masking not used)
Query!
Who is / are masked / blinded?
Query!
Query!
Query!
Query!
Intervention assignment
Parallel
Query!
Other design features
Query!
Phase
NA
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Completed
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
4/04/2017
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
30/04/2021
Query!
Sample size
Target
Query!
Accrual to date
Query!
Final
4579
Query!
Recruitment in Australia
Recruitment state(s)
Query!
Recruitment hospital [1]
0
0
The Prince Charles Hospital - Chermside
Query!
Recruitment hospital [2]
0
0
St Vincents Hospital Melbourne - Melbourne
Query!
Recruitment hospital [3]
0
0
Research Center Perth - Perth
Query!
Recruitment hospital [4]
0
0
Research Center Sydney - Sydney
Query!
Recruitment hospital [5]
0
0
Wollongong Research Center - Wollongong
Query!
Recruitment postcode(s) [1]
0
0
- Chermside
Query!
Recruitment postcode(s) [2]
0
0
- Melbourne
Query!
Recruitment postcode(s) [3]
0
0
- Perth
Query!
Recruitment postcode(s) [4]
0
0
- Sydney
Query!
Recruitment postcode(s) [5]
0
0
- Wollongong
Query!
Recruitment outside Australia
Country [1]
0
0
Argentina
Query!
State/province [1]
0
0
Buenos Aires
Query!
Country [2]
0
0
Austria
Query!
State/province [2]
0
0
Wien
Query!
Country [3]
0
0
Bahrain
Query!
State/province [3]
0
0
Manama
Query!
Country [4]
0
0
Bangladesh
Query!
State/province [4]
0
0
Dhaka
Query!
Country [5]
0
0
Belgium
Query!
State/province [5]
0
0
Aalst
Query!
Country [6]
0
0
Belgium
Query!
State/province [6]
0
0
Bonheiden
Query!
Country [7]
0
0
Belgium
Query!
State/province [7]
0
0
Bruxelles
Query!
Country [8]
0
0
Belgium
Query!
State/province [8]
0
0
Charleroi
Query!
Country [9]
0
0
Belgium
Query!
State/province [9]
0
0
Hasselt
Query!
Country [10]
0
0
Belgium
Query!
State/province [10]
0
0
Liège
Query!
Country [11]
0
0
Bulgaria
Query!
State/province [11]
0
0
Plovdiv
Query!
Country [12]
0
0
Bulgaria
Query!
State/province [12]
0
0
Sofia
Query!
Country [13]
0
0
Czechia
Query!
State/province [13]
0
0
Brno
Query!
Country [14]
0
0
Czechia
Query!
State/province [14]
0
0
Praha
Query!
Country [15]
0
0
Denmark
Query!
State/province [15]
0
0
Roskilde
Query!
Country [16]
0
0
Estonia
Query!
State/province [16]
0
0
Tallinn
Query!
Country [17]
0
0
France
Query!
State/province [17]
0
0
Annecy
Query!
Country [18]
0
0
France
Query!
State/province [18]
0
0
Caen
Query!
Country [19]
0
0
France
Query!
State/province [19]
0
0
Créteil
Query!
Country [20]
0
0
France
Query!
State/province [20]
0
0
Dijon
Query!
Country [21]
0
0
France
Query!
State/province [21]
0
0
Marseille
Query!
Country [22]
0
0
France
Query!
State/province [22]
0
0
Massy
Query!
Country [23]
0
0
France
Query!
State/province [23]
0
0
Metz
Query!
Country [24]
0
0
France
Query!
State/province [24]
0
0
Montauban
Query!
Country [25]
0
0
France
Query!
State/province [25]
0
0
Montpellier
Query!
Country [26]
0
0
France
Query!
State/province [26]
0
0
Nantes
Query!
Country [27]
0
0
France
Query!
State/province [27]
0
0
Nîmes
Query!
Country [28]
0
0
France
Query!
State/province [28]
0
0
Paris
Query!
Country [29]
0
0
France
Query!
State/province [29]
0
0
Rouen
Query!
Country [30]
0
0
France
Query!
State/province [30]
0
0
Saint-Denis
Query!
Country [31]
0
0
Germany
Query!
State/province [31]
0
0
Homburg
Query!
Country [32]
0
0
Germany
Query!
State/province [32]
0
0
Landshut
Query!
Country [33]
0
0
Hungary
Query!
State/province [33]
0
0
Budapest
Query!
Country [34]
0
0
Hungary
Query!
State/province [34]
0
0
Szeged
Query!
Country [35]
0
0
India
Query!
State/province [35]
0
0
Chennai
Query!
Country [36]
0
0
India
Query!
State/province [36]
0
0
Coimbatore
Query!
Country [37]
0
0
India
Query!
State/province [37]
0
0
Surat
Query!
Country [38]
0
0
Israel
Query!
State/province [38]
0
0
Haifa
Query!
Country [39]
0
0
Israel
Query!
State/province [39]
0
0
Jerusalem
Query!
Country [40]
0
0
Israel
Query!
State/province [40]
0
0
Petah tikva
Query!
Country [41]
0
0
Israel
Query!
State/province [41]
0
0
Safed
Query!
Country [42]
0
0
Italy
Query!
State/province [42]
0
0
Andria
Query!
Country [43]
0
0
Italy
Query!
State/province [43]
0
0
Cagliari
Query!
Country [44]
0
0
Italy
Query!
State/province [44]
0
0
Caserta
Query!
Country [45]
0
0
Italy
Query!
State/province [45]
0
0
Catania
Query!
Country [46]
0
0
Italy
Query!
State/province [46]
0
0
Messina
Query!
Country [47]
0
0
Italy
Query!
State/province [47]
0
0
Milan
Query!
Country [48]
0
0
Italy
Query!
State/province [48]
0
0
Roma
Query!
Country [49]
0
0
Italy
Query!
State/province [49]
0
0
Rome
Query!
Country [50]
0
0
Italy
Query!
State/province [50]
0
0
Rozzano
Query!
Country [51]
0
0
Italy
Query!
State/province [51]
0
0
Treviglio
Query!
Country [52]
0
0
Italy
Query!
State/province [52]
0
0
Vimercate
Query!
Country [53]
0
0
Japan
Query!
State/province [53]
0
0
Fukuoka
Query!
Country [54]
0
0
Japan
Query!
State/province [54]
0
0
Gifu
Query!
Country [55]
0
0
Japan
Query!
State/province [55]
0
0
Ichinomiya
Query!
Country [56]
0
0
Japan
Query!
State/province [56]
0
0
Kawasaki
Query!
Country [57]
0
0
Japan
Query!
State/province [57]
0
0
Nagakute
Query!
Country [58]
0
0
Japan
Query!
State/province [58]
0
0
Nagoya
Query!
Country [59]
0
0
Japan
Query!
State/province [59]
0
0
Osaka
Query!
Country [60]
0
0
Japan
Query!
State/province [60]
0
0
Tokyo
Query!
Country [61]
0
0
Japan
Query!
State/province [61]
0
0
Toyoake
Query!
Country [62]
0
0
Korea, Republic of
Query!
State/province [62]
0
0
Seoul
Query!
Country [63]
0
0
Netherlands
Query!
State/province [63]
0
0
's Hertogenbosch
Query!
Country [64]
0
0
Netherlands
Query!
State/province [64]
0
0
Arnhem
Query!
Country [65]
0
0
Netherlands
Query!
State/province [65]
0
0
Breda
Query!
Country [66]
0
0
Netherlands
Query!
State/province [66]
0
0
Dordrecht
Query!
Country [67]
0
0
Netherlands
Query!
State/province [67]
0
0
Eindhoven
Query!
Country [68]
0
0
Netherlands
Query!
State/province [68]
0
0
Emmen
Query!
Country [69]
0
0
Netherlands
Query!
State/province [69]
0
0
Enschede
Query!
Country [70]
0
0
Netherlands
Query!
State/province [70]
0
0
Nieuwegein
Query!
Country [71]
0
0
Netherlands
Query!
State/province [71]
0
0
Rotterdam
Query!
Country [72]
0
0
Netherlands
Query!
State/province [72]
0
0
Terneuzen
Query!
Country [73]
0
0
Netherlands
Query!
State/province [73]
0
0
The Hague
Query!
Country [74]
0
0
North Macedonia
Query!
State/province [74]
0
0
Skopje
Query!
Country [75]
0
0
Poland
Query!
State/province [75]
0
0
Krakow
Query!
Country [76]
0
0
Poland
Query!
State/province [76]
0
0
Kraków
Query!
Country [77]
0
0
Poland
Query!
State/province [77]
0
0
Lubin
Query!
Country [78]
0
0
Poland
Query!
State/province [78]
0
0
Poznan
Query!
Country [79]
0
0
Poland
Query!
State/province [79]
0
0
Wroclaw
Query!
Country [80]
0
0
Saudi Arabia
Query!
State/province [80]
0
0
Jeddah
Query!
Country [81]
0
0
Saudi Arabia
Query!
State/province [81]
0
0
Riyadh
Query!
Country [82]
0
0
Serbia
Query!
State/province [82]
0
0
Belgrade
Query!
Country [83]
0
0
Serbia
Query!
State/province [83]
0
0
Sremska Kamenica
Query!
Country [84]
0
0
Singapore
Query!
State/province [84]
0
0
Singapore
Query!
Country [85]
0
0
Slovenia
Query!
State/province [85]
0
0
Ljubljana
Query!
Country [86]
0
0
Spain
Query!
State/province [86]
0
0
Alicante
Query!
Country [87]
0
0
Spain
Query!
State/province [87]
0
0
Barcelona
Query!
Country [88]
0
0
Spain
Query!
State/province [88]
0
0
El Palmar
Query!
Country [89]
0
0
Spain
Query!
State/province [89]
0
0
Huelva
Query!
Country [90]
0
0
Spain
Query!
State/province [90]
0
0
Madrid
Query!
Country [91]
0
0
Spain
Query!
State/province [91]
0
0
Santander
Query!
Country [92]
0
0
Spain
Query!
State/province [92]
0
0
Vigo
Query!
Country [93]
0
0
Sweden
Query!
State/province [93]
0
0
Gävle
Query!
Country [94]
0
0
Sweden
Query!
State/province [94]
0
0
Örebro
Query!
Country [95]
0
0
Switzerland
Query!
State/province [95]
0
0
Bern
Query!
Country [96]
0
0
Switzerland
Query!
State/province [96]
0
0
Fribourg
Query!
Country [97]
0
0
Switzerland
Query!
State/province [97]
0
0
Geneva
Query!
Country [98]
0
0
Switzerland
Query!
State/province [98]
0
0
Liestal
Query!
Country [99]
0
0
Switzerland
Query!
State/province [99]
0
0
Lugano
Query!
Country [100]
0
0
Switzerland
Query!
State/province [100]
0
0
Zürich
Query!
Country [101]
0
0
United Kingdom
Query!
State/province [101]
0
0
Blackburn
Query!
Country [102]
0
0
United Kingdom
Query!
State/province [102]
0
0
Bournemouth
Query!
Country [103]
0
0
United Kingdom
Query!
State/province [103]
0
0
Brighton
Query!
Country [104]
0
0
United Kingdom
Query!
State/province [104]
0
0
Bristol
Query!
Country [105]
0
0
United Kingdom
Query!
State/province [105]
0
0
Derry
Query!
Country [106]
0
0
United Kingdom
Query!
State/province [106]
0
0
London
Query!
Country [107]
0
0
United Kingdom
Query!
State/province [107]
0
0
Manchester
Query!
Country [108]
0
0
United Kingdom
Query!
State/province [108]
0
0
Newcastle Upon Tyne
Query!
Country [109]
0
0
United Kingdom
Query!
State/province [109]
0
0
Stevenage
Query!
Country [110]
0
0
United Kingdom
Query!
State/province [110]
0
0
Stoke-on-Trent
Query!
Country [111]
0
0
United Kingdom
Query!
State/province [111]
0
0
Wolverhampton
Query!
Country [112]
0
0
United Kingdom
Query!
State/province [112]
0
0
Worcester
Query!
Country [113]
0
0
Vietnam
Query!
State/province [113]
0
0
Hanoi
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Query!
Name
ECRI bv
Query!
Address
Query!
Country
Query!
Other collaborator category [1]
0
0
Commercial sector/industry
Query!
Name [1]
0
0
Cardialysis B.V.
Query!
Address [1]
0
0
Query!
Country [1]
0
0
Query!
Other collaborator category [2]
0
0
Other
Query!
Name [2]
0
0
European Cardiovascular Research Center
Query!
Address [2]
0
0
Query!
Country [2]
0
0
Query!
Other collaborator category [3]
0
0
Other
Query!
Name [3]
0
0
University of Bern
Query!
Address [3]
0
0
Query!
Country [3]
0
0
Query!
Other collaborator category [4]
0
0
Commercial sector/industry
Query!
Name [4]
0
0
Terumo Medical Corporation
Query!
Address [4]
0
0
Query!
Country [4]
0
0
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
The study compares two lengths of medication therapy (a shortened versus a prolonged dual antiplatelet therapy) in order to prevent thrombus (blood cloth) formation after the successfully treatment for coronary heart disease with a drug covered stent (metallic tube). This comparison will be done in patients who, compared to the average patient, are more likely to suffer from complications on antiplatelet therapy (bleeding). Both durations are within the current medical recommendations. The aim of this study is to help improve further standard antiplatelet duration guidelines.
Query!
Trial website
https://clinicaltrials.gov/study/NCT03023020
Query!
Trial related presentations / publications
Authors/Task Force members; Windecker S, Kolh P, Alfonso F, Collet JP, Cremer J, Falk V, Filippatos G, Hamm C, Head SJ, Juni P, Kappetein AP, Kastrati A, Knuuti J, Landmesser U, Laufer G, Neumann FJ, Richter DJ, Schauerte P, Sousa Uva M, Stefanini GG, Taggart DP, Torracca L, Valgimigli M, Wijns W, Witkowski A. 2014 ESC/EACTS Guidelines on myocardial revascularization: The Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS)Developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI). Eur Heart J. 2014 Oct 1;35(37):2541-619. doi: 10.1093/eurheartj/ehu278. Epub 2014 Aug 29. No abstract available. Roffi M, Patrono C, Collet JP, Mueller C, Valgimigli M, Andreotti F, Bax JJ, Borger MA, Brotons C, Chew DP, Gencer B, Hasenfuss G, Kjeldsen K, Lancellotti P, Landmesser U, Mehilli J, Mukherjee D, Storey RF, Windecker S; ESC Scientific Document Group. 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC). Eur Heart J. 2016 Jan 14;37(3):267-315. doi: 10.1093/eurheartj/ehv320. Epub 2015 Aug 29. No abstract available. Levine GN, Bates ER, Bittl JA, Brindis RG, Fihn SD, Fleisher LA, Granger CB, Lange RA, Mack MJ, Mauri L, Mehran R, Mukherjee D, Newby LK, O'Gara PT, Sabatine MS, Smith PK, Smith SC, Jr. 2016 ACC/AHA Guideline Focused Update on Duration of Dual Antiplatelet Therapy in Patients With Coronary Artery Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines: An Update of the 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention, 2011 ACCF/AHA Guideline for Coronary Artery Bypass Graft Surgery, 2012 ACC/AHA/ACP/AATS/PCNA/SCAI/STS Guideline for the Diagnosis and Management of Patients With Stable Ischemic Heart Disease, 2013 ACCF/AHA Guideline for the Management of ST-Elevation Myocardial Infarction, 2014 AHA/ACC Guideline for the Management of Patients With Non-ST-Elevation Acute Coronary Syndromes, and 2014 ACC/AHA Guideline on Perioperative Cardiovascular Evaluation and Management of Patients Undergoing Noncardiac Surgery. Circulation 2016 Smits PC, Frigoli E, Vranckx P, Ozaki Y, Morice MC, Chevalier B, Onuma Y, Windecker S, Tonino PAL, Roffi M, Lesiak M, Mahfoud F, Bartunek J, Hildick-Smith D, Colombo A, Stankovic G, Iniguez A, Schultz C, Kornowski R, Ong PJL, Alasnag M, Rodriguez AE, Paradies V, Kala P, Kedev S, Al Mafragi A, Dewilde W, Heg D, Valgimigli M; MASTER DAPT Investigators. Abbreviated Antiplatelet Therapy After Coronary Stenting in Patients With Myocardial Infarction at High Bleeding Risk. J Am Coll Cardiol. 2022 Sep 27;80(13):1220-1237. doi: 10.1016/j.jacc.2022.07.016. Valgimigli M, Frigoli E, Vranckx P, Ozaki Y, Morice MC, Chevalier B, Onuma Y, Windecker S, Delorme L, Kala P, Kedev S, Abhaichand RK, Velchev V, Dewilde W, Podolec J, Leibundgut G, Topic D, Schultz C, Stankovic G, Lee A, Johnson T, Tonino PAL, Klotzka A, Lesiak M, Lopes RD, Smits PC, Heg D; MASTER DAPT Investigators. Impact of Medication Nonadherence in a Clinical Trial of Dual Antiplatelet Therapy. J Am Coll Cardiol. 2022 Aug 23;80(8):766-778. doi: 10.1016/j.jacc.2022.04.065. Valgimigli M, Smits PC, Frigoli E, Bongiovanni D, Tijssen J, Hovasse T, Mafragi A, Ruifrok WT, Karageorgiev D, Aminian A, Garducci S, Merkely B, Routledge H, Ando K, Diaz Fernandez JF, Cuisset T, Nesa Malik FT, Halabi M, Belle L, Din J, Beygui F, Abhyankar A, Reczuch K, Pedrazzini G, Heg D, Vranckx P; MASTER DAPT Investigators. Duration of antiplatelet therapy after complex percutaneous coronary intervention in patients at high bleeding risk: a MASTER DAPT trial sub-analysis. Eur Heart J. 2022 Sep 1;43(33):3100-3114. doi: 10.1093/eurheartj/ehac284. Smits PC, Frigoli E, Tijssen J, Juni P, Vranckx P, Ozaki Y, Morice MC, Chevalier B, Onuma Y, Windecker S, Tonino PAL, Roffi M, Lesiak M, Mahfoud F, Bartunek J, Hildick-Smith D, Colombo A, Stankovic G, Iniguez A, Schultz C, Kornowski R, Ong PJL, Alasnag M, Rodriguez AE, Moschovitis A, Laanmets P, Heg D, Valgimigli M; MASTER DAPT Investigators. Abbreviated Antiplatelet Therapy in Patients at High Bleeding Risk With or Without Oral Anticoagulant Therapy After Coronary Stenting: An Open-Label, Randomized, Controlled Trial. Circulation. 2021 Oct 12;144(15):1196-1211. doi: 10.1161/CIRCULATIONAHA.121.056680. Epub 2021 Aug 29. Valgimigli M, Frigoli E, Heg D, Tijssen J, Juni P, Vranckx P, Ozaki Y, Morice MC, Chevalier B, Onuma Y, Windecker S, Tonino PAL, Roffi M, Lesiak M, Mahfoud F, Bartunek J, Hildick-Smith D, Colombo A, Stankovic G, Iniguez A, Schultz C, Kornowski R, Ong PJL, Alasnag M, Rodriguez AE, Moschovitis A, Laanmets P, Donahue M, Leonardi S, Smits PC; MASTER DAPT Investigators. Dual Antiplatelet Therapy after PCI in Patients at High Bleeding Risk. N Engl J Med. 2021 Oct 28;385(18):1643-1655. doi: 10.1056/NEJMoa2108749. Epub 2021 Aug 28. Vlieger S, Danzi GB, Kauer F, Oemrawsingh RM, Stojkovic S, IJsselmuiden AJJ, Routledge H, Laanmets P, Roffi M, Frobert O, Baello P, Wlodarczak A, Puentes A, Polad J, Hildick-Smith D. One-year performance of thin-strut cobalt chromium sirolimus-eluting stent versus thicker strut stainless steel biolimus-eluting coronary stent: a propensity-matched analysis of two international all-comers registries. Coron Artery Dis. 2021 Aug 1;32(5):391-396. doi: 10.1097/MCA.0000000000000958. Frigoli E, Smits P, Vranckx P, Ozaki Y, Tijssen J, Juni P, Morice MC, Onuma Y, Windecker S, Frenk A, Spaulding C, Chevalier B, Barbato E, Tonino P, Hildick-Smith D, Roffi M, Kornowski R, Schultz C, Lesiak M, Iniguez A, Colombo A, Alasnag M, Mullasari A, James S, Stankovic G, Ong PJL, Rodriguez AE, Mahfoud F, Bartunek J, Moschovitis A, Laanmets P, Leonardi S, Heg D, Sunnaker M, Valgimigli M. Design and rationale of the Management of High Bleeding Risk Patients Post Bioresorbable Polymer Coated Stent Implantation With an Abbreviated Versus Standard DAPT Regimen (MASTER DAPT) Study. Am Heart J. 2019 Mar;209:97-105. doi: 10.1016/j.ahj.2018.10.009. Epub 2018 Nov 22.
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
M. Valgimigli, Prof.
Query!
Address
0
0
Cardiocentro Ticino Foundation, Lugano, Switzerland
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for scientific queries
Data sharing statement
Will individual participant data (IPD) for this trial be available (including data dictionaries)?
Undecided
Query!
No/undecided IPD sharing reason/comment
Query!
What supporting documents are/will be available?
No Supporting Document Provided
Results publications and other study-related documents
No documents have been uploaded by study researchers.
Results not provided in
https://clinicaltrials.gov/study/NCT03023020